Literature DB >> 10734178

Ras/mitogen-activated protein kinase mediates norepinephrine-induced phospholipase D activation in rabbit aortic smooth muscle cells by a phosphorylation-dependent mechanism.

M M Muthalif1, J H Parmentier, I F Benter, N Karzoun, A Ahmed, Z Khandekar, M Z Adl, S Bourgoin, K U Malik.   

Abstract

Phospholipase D (PLD) activity is regulated by phosphatidylinositol 4,5-biphosphate, protein kinase C (PKC), ADP-ribosylation factor, and Rho. The present study was designed to investigate the mechanism of norepinephrine (NE)-mediated PLD activation in rabbit aortic vascular smooth muscle cells (VSMC). NE (10 microM) caused activation of PLD, as measured by the production of phosphatidylethanol in [(3)H]oleic acid-labeled cells. NE also increased PKC activity in VSMC. However, treatment of cells with bisindolylmaleimide, a PKC inhibitor, or long-term treatment with phorbol-12-myristate-13-acetate that depletes PKC did not decrease NE-induced activation of PLD. NE-stimulated PLD activity was attenuated by farnesyl transferase inhibitors (FPT III and SCH-56582), which reduce activation of both Ras and mitogen-activated protein (MAP) kinase. Moreover, transfection of VSMC with a dominant negative Ras resulted in inhibition of NE-stimulated MAP kinase and PLD activities. Treatment of cells with PD-98059, a MAP kinase kinase inhibitor, also reduced NE-stimulated PLD activity. These data suggest that NE-stimulated PLD activity is mediated via activation of Ras and MAP kinase in rabbit VSMC. To study the mechanism of activation of PLD by Ras/MAP kinase, NE-induced phosphorylation of PLD was examined. In VSMC, PLD of molecular mass 120 kDa was identified with polyclonal PLD antibody. Phosphorylation of PLD by NE, measured as (32)P incorporation into PLD, was inhibited by PD-98059. Moreover, PLD immunoprecipitated from VSMC lysates was phosphorylated in vitro by MAP kinase. Collectively, these results show a novel pathway for activation of PLD that appears to be mediated through Ras/MAP kinase pathway by a mechanism involving phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10734178

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Vascular smooth muscle Jak2 mediates angiotensin II-induced hypertension via increased levels of reactive oxygen species.

Authors:  Annet Kirabo; Patrick N Kearns; Yagna P Jarajapu; Jennifer M Sasser; Suk Paul Oh; Maria B Grant; Hideko Kasahara; Arturo J Cardounel; Chris Baylis; Kay-Uwe Wagner; Peter P Sayeski
Journal:  Cardiovasc Res       Date:  2011-02-24       Impact factor: 10.787

2.  Norepinephrine acting on adventitial fibroblasts stimulates vascular smooth muscle cell proliferation via promoting small extracellular vesicle release.

Authors:  Chao Ye; Fen Zheng; Tao Xu; Nan Wu; Ying Tong; Xiao-Qing Xiong; Ye-Bo Zhou; Jue-Jin Wang; Qi Chen; Yue-Hua Li; Guo-Qing Zhu; Ying Han
Journal:  Theranostics       Date:  2022-06-06       Impact factor: 11.600

Review 3.  Phospholipase D/phosphatidic acid signal transduction: role and physiological significance in lung.

Authors:  Rhett Cummings; Narasimham Parinandi; Lixin Wang; Peter Usatyuk; Viswanathan Natarajan
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

4.  Involvement of phospholipases D1 and D2 in sphingosine 1-phosphate-induced ERK (extracellular-signal-regulated kinase) activation and interleukin-8 secretion in human bronchial epithelial cells.

Authors:  Lixin Wang; Rhett Cummings; Peter Usatyuk; Andrew Morris; Kaikobad Irani; Viswanathan Natarajan
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

Review 5.  Phospholipase D signaling: orchestration by PIP2 and small GTPases.

Authors:  Paschal A Oude Weernink; Maider López de Jesús; Martina Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-24       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.